Receptor News and Research

RSS

Oral cancer pain and opioid tolerance share a common EGFR mechanism

Epidermal growth factor receptor (EGFR) signaling in the tissue around oral cancers both increases nerve sensitivity and makes opioids less effective, according to new research published in Science Signaling.

29 Jan 2026

Combination therapy improves cognition in Alzheimer’s models

In recent years, research into cannabis and its main psychoactive ingredient, Δ⁹-tetrahydrocannabinol (THC), has unearthed medical benefits including anti-inflammatory and neuroprotective properties.

28 Jan 2026

Four-biomarker blood panel enhances the detection of pancreatic ductal adenocarcinoma

A four-biomarker blood panel of aminopeptidase N (ANPEP), polymeric immunoglobulin receptor (PIGR), CA19-9, and thrombospondin-2 (THBS2) enhanced the detection of pancreatic ductal adenocarcinoma (PDAC) compared to measuring CA19-9 levels alone.

28 Jan 2026

Following the EAT-Lancet diet lowers chronic kidney disease risk

Research shows the EAT-Lancet diet may lower chronic kidney disease risk, emphasizing the importance of diet quality and personalized nutrition in prevention.

28 Jan 2026

Targeted Fab fragments dismantle the allergy trigger

Allergic diseases represent a major global health burden, placing significant strain on healthcare systems worldwide. Severe conditions such as anaphylaxis, asthma, food allergy, and allergic rhinitis are driven by immunoglobulin E (IgE), an antibody that binds to immune cells, including mast cells and basophils.

27 Jan 2026

New trial tests strategies to protect heart health during prostate cancer therapy

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened a phase 2 clinical trial comparing three different strategies for protecting heart health in prostate cancer patients who receive androgen deprivation therapy (ADT), a potentially lifesaving hormone therapy.

26 Jan 2026

Why exercise is essential for restoring fitness after GLP-1-based weight loss

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, improves physical function and cardiorespiratory fitness after diet-induced weight loss in adults with obesity. In contrast, liraglutide alone sustains weight loss but does not significantly improve measured physical fitness outcomes.

26 Jan 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026

Metabolic reprogramming drives prostate cancer progression and treatment resistance

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy (ADT), the disease often progresses to castration-resistant prostate cancer (CRPC).

24 Jan 2026

Scientists discover a non-classical platelet mechanism linked to severe infections

Platelets are small, anucleate blood cells that play an essential role in hemostasis. Their primary task is to recognize vascular injury, become activated, and aggregate via their surface receptor integrin αIIbβ3. This leads to the formation of a stable platelet plug that seals the wound and stops bleeding. When this process becomes dysregulated, however, it can result in vessel-occluding clots - so-called thromboses - which may cause myocardial infarction or stroke.

23 Jan 2026

Myosteatosis: An emerging predictor of outcomes in chronic liver disease

Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of poor clinical outcomes across a spectrum of liver diseases.

22 Jan 2026

Study identifies a powerful strategy to overcome drug resistance in breast cancer

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast cancer by simultaneously targeting two key cell-cycle regulators, CDK2 and CDK4/6.

22 Jan 2026

Long-term proton pump inhibitor use not linked to stomach cancer

The long term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased risk of developing gastric (stomach) cancer, finds a study of Nordic health data published by The BMJ today.

21 Jan 2026

GLP-1 weight-loss drugs show early promise for treating addiction

This systematic review evaluates preclinical and clinical evidence on glucagon-like peptide-1 receptor agonists as potential treatments for substance use disorders. Findings show consistent reductions in drug- and alcohol-seeking behaviors in animal models, while human evidence remains limited, heterogeneous, and preliminary.

21 Jan 2026

Newly discovered survival pathway explains stubborn EGFR-driven lung cancers

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene called EGFR (epidermal growth factor receptor).

21 Jan 2026

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent the most common chronic liver diseases in Western populations, driven largely by obesity and insulin resistance.

21 Jan 2026

Receptor News and Research

Oral cancer pain and opioid tolerance share a common EGFR mechanism

Combination therapy improves cognition in Alzheimer’s models

Four-biomarker blood panel enhances the detection of pancreatic ductal adenocarcinoma

Following the EAT-Lancet diet lowers chronic kidney disease risk

Targeted Fab fragments dismantle the allergy trigger

New trial tests strategies to protect heart health during prostate cancer therapy

Why exercise is essential for restoring fitness after GLP-1-based weight loss

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

Metabolic reprogramming drives prostate cancer progression and treatment resistance

Scientists discover a non-classical platelet mechanism linked to severe infections

Myosteatosis: An emerging predictor of outcomes in chronic liver disease

Study identifies a powerful strategy to overcome drug resistance in breast cancer

Long-term proton pump inhibitor use not linked to stomach cancer

GLP-1 weight-loss drugs show early promise for treating addiction

Newly discovered survival pathway explains stubborn EGFR-driven lung cancers

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

High-dose flu shots lower hospitalization risk in older adults

Study reveals how ketogenic diet protects against epilepsy seizures

Purdue-developed LENN system enhances stability and targeting of mRNA cancer therapies

Study provides a new paradigm for managing transplant‑related immune complications

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News